FUROSEMIDE-AFT SOLUTION FOR INJECTION 20MG/2ML

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Therapeutic

Prescription Only

INJECTION, SOLUTION

**4.2 DOSE AND METHOD OF ADMINISTRATION** **Adults** Parenteral therapy with Furosemide – AFT should be used only in patients unable to take oral medication or in emergency situations and should be replaced with oral therapy as soon as practical. To achieve optimum efficacy and suppress counter-regulation, a continuous furosemide (frusemide) infusion is generally preferred to repeat bolus injections. Intramuscular administration must be restricted to exceptional cases where neither oral nor intravenous administration are feasible. It must be noted that intramuscular injection is not suitable for the treatment of acute conditions such as pulmonary oedema. **_Oedema_** The usual initial dose of Furosemide – AFT is 20 to 40 mg given as a single dose, injected intramuscularly or intravenously. The intravenous dose should be given slowly (see Section 4.4 Special warnings and precautions for use – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Ordinarily a prompt diuresis ensues. If needed, another dose may be administered in the same manner 2 hours later, or the dose may be increased. The dose may be raised by 20 mg and given not sooner than 2 hours after the previous dose, until the desired diuretic effect has been obtained. This individually determined single dose should then be given once or twice daily. Therapy should be individualised according to patient response to gain maximal therapeutic response and to determine the minimal dose needed to maintain that response. Close medical supervision is necessary. If the physician elects to use high dose parenteral therapy, add the Furosemide – AFT to either Sodium Chloride Injection or Lactated Ringer's Injection, and administer as a controlled intravenous infusion at a rate not greater than 4 mg/min. Furosemide – AFT is a buffered alkaline solution. **_Acute Pulmonary Oedema_** The usual initial dose of Furosemide – AFT is 40 mg injected slowly intravenously (see Section 4.4 Special warnings and precautions for use – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). If a satisfactory response does not occur, a further dose of 20–40 mg is injected after 20 minutes. If necessary, additional therapy (e.g. digitalis, oxygen) may be administered concomitantly. **Infants and Children** Parenteral therapy should be used only in patients unable to take oral medication or in emergency situations, and should be replaced with oral therapy as soon as practical. The recommended dose of Furosemide – AFT (intravenously or intramuscularly) in infants and children is 1 mg/kg body weight and should be given slowly under close medical supervision up to a maximum of 20 mg. Furosemide-AFT Injection should be inspected visually for particulate matter and discolouration before administration. Do not use if solution is discoloured. Furosemide-AFT is for single use in one patient only. Discard any residue. Although the chemical stability of diluted Furosemide – AFT (diluted with 0.9 % NaCl or Lactated Ringer's Injection to concentration 1 mg/ml of furosemide) has been demonstrated for storage at 30 °C for 24 hours, the diluted solution should be used as soon as practicable to reduce risk of microbiological hazard. The diluted solution must be protected from light.